Case Studies

Challenge A major public/private investor in a BRIC territory needed help with an investment strategy for building a nationwide radiopharmaceutical infrastructure and capacity in its home country....

Challenge A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.

Alzheimer's due diligence Our client, a major pension fund, was considering an investment opportunity in a Phase III neuroscience company. The company was developing a small molecule to provide...

Alacrita's 510(k) regulatory affairs consultant worked with our UK medical device client to secure 510(k) clearance to for a non-contact respiratory measurement device. She provided strategic...

Oncology Scientific Advisory Board An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor of a novel cancer metabolism target. The...

A pharmaceutical company asked Alacrita to assist in providing an HTA/payer perspective on the proposed label and mechanism of action/clinical positioning for its pain drug, to ensure that the Phase...

A Cambridge MA based therapeutics company asked Alacrita to provide feedback on the Phase III protocol design for its lead drug, specifically from an EU payer perspective. Alacrita’s expert European...

A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and...

A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with pre-clinical testing on pigs, as well as...

Challenge: A clinical stage biotech needed support with its regulatory due diligence activities for products in the respiratory field.

Alacrita was asked to assess the market opportunity for a novel anaemia therapy in order to facilitate discussions with potential partners. Alacrita conducted the assessment in two stages.